James George  Robinson net worth and biography

James Robinson Biography and Net Worth

James Robinson is an independent director of Nymox Pharmaceutical Corporation, a company that specializes in research and development of therapeutics and diagnostics, with an emphasis on products targeted to the rapidly aging male population in developed economies. Robinson has been a member of Nymox’s board of directors since 2015.

He is also the founder, chairman and CEO of Morgan Creek Entertainment, a leading independent film production company. During his tenure, Morgan Creek has produced an array of successful, critically-acclaimed feature films, including “Ace Ventura: Pet Detective,” “True Romance,” and “Robin Hood: Prince of Thieves.”

Before his career in film production took off, Robinson had an array of work experiences, including a stint in the Army, professional photography, and a car cleaning business. In 1975, he purchased a failing Subaru distributorship and managed to turn it around to the point that when he sold it in 1988, the company was distributing to 94 dealers throughout the Midwest.

He entered the film industry in 1979 at the suggestion of an attorney friend from Los Angeles. He worked in development and finance and had his first production credit in the 1984 film, “The Stone Boy.” In 1988, he formed Morgan Creek Productions (rebranded to Morgan Creek Entertainment in 2017) with his partner, Joe Roth.

The company’s first success was "Robin Hood: Prince of Thieves," starring Kevin Costner and making over $400 million worldwide. Since then, they have released numerous box-office hits. Though Robinson remains chairman and CEO, two of his sons run the day-to-day operations.

A Maryland native, Robinson lives in Baltimore with his wife Barbara and their five children, and he commutes to Los Angeles. He attended the University of Maryland.

What is James George Robinson's net worth?

The estimated net worth of James George Robinson is at least $0.00 as of May 2nd, 2022. Mr. Robinson owns 4,702,065 shares of Nymox Pharmaceutical stock worth more than $0 as of December 1st. This net worth evaluation does not reflect any other assets that Mr. Robinson may own. Learn More about James George Robinson's net worth.

How do I contact James George Robinson?

The corporate mailing address for Mr. Robinson and other Nymox Pharmaceutical executives is BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2. Nymox Pharmaceutical can also be reached via phone at (800) 936-9669 and via email at [email protected]. Learn More on James George Robinson's contact information.

Has James George Robinson been buying or selling shares of Nymox Pharmaceutical?

James George Robinson has not been actively trading shares of Nymox Pharmaceutical within the last three months. Most recently, on Monday, May 2nd, James George Robinson bought 1,151,515 shares of Nymox Pharmaceutical stock. The stock was acquired at an average cost of $1.65 per share, with a total value of $1,899,999.75. Following the completion of the transaction, the director now directly owns 4,702,065 shares of the company's stock, valued at $7,758,407.25. Learn More on James George Robinson's trading history.

James George Robinson Insider Trading History at Nymox Pharmaceutical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/2/2022Buy1,151,515$1.65$1,899,999.754,702,065View SEC Filing Icon  
4/21/2021Buy13,000$2.08$27,040.003,512,550View SEC Filing Icon  
7/9/2019Buy7,000$1.63$11,410.003,503,550View SEC Filing Icon  
7/5/2019Buy9,000$1.45$13,050.003,496,550View SEC Filing Icon  
7/3/2019Buy8,000$1.54$12,320.003,487,550View SEC Filing Icon  
7/1/2019Buy9,000$1.37$12,330.003,472,750View SEC Filing Icon  
6/27/2019Buy9,000$1.56$14,040.003,453,283View SEC Filing Icon  
6/25/2019Buy9,000$1.73$15,570.003,441,950View SEC Filing Icon  
6/20/2019Buy9,000$1.77$15,930.003,434,550View SEC Filing Icon  
6/18/2019Buy9,000$1.67$15,030.003,408,650View SEC Filing Icon  
6/13/2019Buy8,000$1.42$11,360.003,408,550View SEC Filing Icon  
6/11/2019Buy9,000$1.46$13,140.003,391,550View SEC Filing Icon  
6/5/2019Buy11,000$1.55$17,050.003,362,750View SEC Filing Icon  
6/3/2019Buy9,000$1.62$14,580.003,362,550View SEC Filing Icon  
5/30/2019Buy8,500$1.76$14,960.003,335,150View SEC Filing Icon  
5/28/2019Buy9,000$1.68$15,120.003,335,050View SEC Filing Icon  
5/24/2019Buy8,000$1.59$12,720.003,318,050View SEC Filing Icon  
12/12/2018Buy6,000$1.71$10,260.003,305,313View SEC Filing Icon  
12/10/2018Buy7,500$1.62$12,150.003,294,313View SEC Filing Icon  
12/6/2018Buy1,400$1.74$2,436.003,279,813View SEC Filing Icon  
12/4/2018Buy7,500$1.72$12,900.003,278,413View SEC Filing Icon  
11/29/2018Buy7,000$1.81$12,670.003,265,913View SEC Filing Icon  
11/27/2018Buy8,000$1.71$13,680.003,258,913View SEC Filing Icon  
11/20/2018Buy6,000$1.78$10,680.003,244,913View SEC Filing Icon  
11/16/2018Buy6,000$1.93$11,580.003,235,913View SEC Filing Icon  
11/13/2018Buy7,000$2.00$14,000.003,229,913View SEC Filing Icon  
11/9/2018Buy13,000$2.09$27,170.003,210,240View SEC Filing Icon  
11/7/2018Buy363$2.04$740.523,209,913View SEC Filing Icon  
11/2/2018Buy7,000$1.98$13,860.003,204,350View SEC Filing Icon  
10/31/2018Buy12,000$1.79$21,480.003,184,550View SEC Filing Icon  
10/25/2018Buy10,000$1.62$16,200.003,168,950View SEC Filing Icon  
10/22/2018Buy8,000$1.67$13,360.0013,340View SEC Filing Icon  
3/26/2018Buy8,000$3.93$31,440.003,159,550View SEC Filing Icon  
3/20/2018Buy8,000$4.02$32,160.003,152,550View SEC Filing Icon  
3/15/2018Buy8,000$3.58$28,640.003,144,550View SEC Filing Icon  
3/9/2018Buy8,000$3.48$27,840.003,136,550View SEC Filing Icon  
2/21/2018Buy6,000$3.23$19,380.003,123,250View SEC Filing Icon  
2/16/2018Buy7,000$3.27$22,890.00View SEC Filing Icon  
2/12/2018Buy8,000$3.27$26,160.003,107,850View SEC Filing Icon  
2/8/2018Buy10,000$3.37$33,700.003,091,050View SEC Filing Icon  
2/2/2018Buy5,000$3.47$17,350.003,090,550View SEC Filing Icon  
1/18/2018Buy3,000$3.14$9,420.003,085,550View SEC Filing Icon  
8/3/2017Buy10,000$3.73$37,300.003,077,550View SEC Filing Icon  
8/2/2017Buy5,000$3.79$18,950.003,077,550View SEC Filing Icon  
8/1/2017Buy15,000$3.72$55,800.003,062,550View SEC Filing Icon  
7/7/2017Buy11,500$4.00$46,000.003,046,550View SEC Filing Icon  
7/6/2017Buy3,000$3.92$11,760.003,046,550View SEC Filing Icon  
7/5/2017Buy5,000$3.97$19,850.003,046,550View SEC Filing Icon  
6/28/2017Buy8,500$4.09$34,765.003,040,050View SEC Filing Icon  
6/26/2017Buy15,000$3.80$57,000.003,027,550View SEC Filing Icon  
6/21/2017Buy15,000$3.77$56,550.003,008,150View SEC Filing Icon  
6/20/2017Buy5,000$3.76$18,800.003,008,150View SEC Filing Icon  
6/19/2017Buy5,000$3.79$18,950.003,008,150View SEC Filing Icon  
5/30/2017Buy54,500$3.81$207,645.002,957,550View SEC Filing Icon  
3/8/2017Buy50,000$3.59$179,500.002,906,078View SEC Filing Icon  
8/10/2016Buy500$2.47$1,235.002,907,550View SEC Filing Icon  
8/4/2016Buy7,000$3.41$23,870.002,902,550View SEC Filing Icon  
7/29/2016Buy22,500$3.86$86,850.002,880,050View SEC Filing Icon  
7/20/2016Buy10,000$3.33$33,300.002,870,050View SEC Filing Icon  
7/7/2016Buy20,000$3.28$65,600.002,850,050View SEC Filing Icon  
6/29/2016Buy17,500$3.53$61,775.002,833,050View SEC Filing Icon  
6/24/2016Buy22,500$2.97$66,825.002,810,050View SEC Filing Icon  
5/13/2016Buy28,010$2.31$64,703.102,782,550View SEC Filing Icon  
5/3/2016Buy6,990$2.36$16,496.402,777,050View SEC Filing Icon  
4/29/2016Buy15,000$2.27$34,050.002,762,550View SEC Filing Icon  
4/15/2016Buy39,500$2.39$94,405.002,722,550View SEC Filing Icon  
4/1/2016Buy20,500$2.40$49,200.002,701,050View SEC Filing Icon  
3/24/2016Buy40,000$2.29$91,600.002,659,050View SEC Filing Icon  
1/12/2016Buy20,000$2.44$48,800.002,657,550View SEC Filing Icon  
1/8/2016Buy95,000$2.90$275,500.002,637,550View SEC Filing Icon  
12/30/2015Buy5,000$3.38$16,900.002,542,550View SEC Filing Icon  
12/29/2015Buy14,000$3.55$49,700.002,542,550View SEC Filing Icon  
12/28/2015Buy6,000$3.79$22,740.002,542,550View SEC Filing Icon  
12/23/2015Buy29,854$3.54$105,683.162,517,550View SEC Filing Icon  
12/18/2015Buy63,334$3.56$225,469.042,487,696View SEC Filing Icon  
12/11/2015Buy46,812$3.51$164,310.122,424,362View SEC Filing Icon  
12/4/2015Buy110,000$3.44$378,400.002,377,550View SEC Filing Icon  
9/3/2015Buy100,000$2.25$225,000.002,267,550View SEC Filing Icon  
See Full Table

James George Robinson Buying and Selling Activity at Nymox Pharmaceutical

This chart shows James George Robinson's buying and selling at Nymox Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nymox Pharmaceutical Company Overview

Nymox Pharmaceutical logo
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.34
Low: $0.19
High: $0.47

2 Week Range

Now: N/A

Volume

932,700 shs

Average Volume

94,622 shs

Market Capitalization

$18.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64